



File No. CT/24/000123

To,

M/s Klinera Global Services,
801, Neelkanth Corporate Park, Opp Vidyavihar Station,
Vidyavihar (West) Vidyavihar (India) - 400086.

Sir,

With reference to your application No. GCT/CT04/FF/2024/45756 dated 03-Oct-2024 please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, **“Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Evixapodlin Administered as 2nd Line Monotherapy in Subjects with Advanced Non-Small Cell Lung Cancer Expressing PD-L1” Protocol no. OX4224-200 amendment 2 dated 05-Feb-2025 with a total of up-to 50 subjects from India** under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

- (i) **Human biological samples i.e. Blood plasma related to clinical trial shall be permitted to be exported for analysis subject to the clearance by port offices of CDSCO. Further, ICMR/DHR permission shall be obtained for export of optional biological samples as per DGFT notification number 72/2023 dated 11.03.2024.**
- (ii) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (iii) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (iv) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (v) the Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

- (vi) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vii) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (viii) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (ix) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;
- (x) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (xi) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (xii) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xiii) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xiv) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xv) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xvi) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority;
- (xvii) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xviii) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial;
- (xix) Merely granting permission to conduct the **clinical trial** with the Investigational Drug Product does not convey or imply that, based on the **clinical trial study data** generated with the investigational drug, permission to market this drug in the country will automatically be granted to you;
- (xx) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India) &
Central Licensing Authority
Stamp

FORM CT-06

(See rules 22,25,26,29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG**

1. The Central Licensing Authority hereby permits **M/s. Klinera Global Services, 801, Neelkanth Corporate Park, Opp Vidyavihar Station, Vidyavihar (West) Vidyavihar (India) - 400086** to conduct clinical trial of the new drug or investigational new drug as per **Protocol no. OX4224-200 amendment 2 dated 05-Feb-2025** in the below mentioned clinical trial sites [As per Annexure].
2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].
3. This permission is subject to the conditions prescribed in Part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date _____

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)&
Central Licensing Authority
Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	Evixapodlin
Therapeutic class:	Anticancer
Dosage form:	Tablets
Composition:	Evixapodlin =500.0000 milligram (mg) In House Specification Active
Indications:	Advanced Non-Small Cell Lung Cancer Expressing PD-L1

Annexure:

Details of clinical trial site:

Sr. No.	Names and address of clinical trial site	Ethics committee details	Name of investigator
1.	SMS Hospital R.K Birla cancer centre, JLN Marg, Jaipur, Rajasthan-302004	Institutional EC, SMS Medical College and Hospital, R.K Birla cancer centre, JLN Marg, Jaipur, Rajasthan-302004 ECR/26/Inst/RJ/2013/RR-19	Dr. Sandeep Kumar Jasuja
2.	Tata Memorial Centre, Dr E Borges Road, Parel, Mumbai-400012	Institutional Ethics Committee Tata Memorial Centre, Dr E Borges Road, Parel, Mumbai-400012 ECR/170/Inst/MH/2013/RR-22	Dr. Minit Jalan Shah
3.	All India Institute of Medical Sciences Room No. 160 A, Dr. B. R. Ambedkar Institute of Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029	AIIMS Institutional EC Room No.-102, 1st Floor, Old OT Block All India Institute of Medical Sciences, Ansari Nagar Delhi, India ECR/538/Inst/DL/2014/RR-20	Dr Sachin Khurana

4.	CIMETS Inamdar Multi speciality Hospital,S.No15, Fatima Nagar, Behind KPCT Mall, Pune 411040	Ethics Committee Inamdar Multispeciality Hospital No15, Fatima Nagar, Behind KPCT Mall, Pune 411040 ECR/357/Inst/MH/2013/RR-20	Dr. Minish Jain
5.	Chittaranjan National Cancer Institute 37, S.P Mukherjee Road. Kolkata-700026. West Bengal, India.	Institutional Ethics Committee Chittaranjan National Cancer Institute 37, S.P Mukherjee Road. Kolkata-700026. West Bengal, India ECR/241/Inst/WB/2013/RR-20	Dr. Kalyan Kusum Mukherjee
6.	VMMC and Safdarjung Hospital, New Delhi, 110029	Institutional Ethics committee-VMMC and Safdarjung Hospital, New Delhi, 110029 ECR/593/Inst/DL/2014/RR-20	Dr. Kaushal Kalra
7.	Artemis hospital Artemis hospital, sector 51, Gurugram, Haryana, 122001	Artemis Health Sciences Institutional Ethics Committee, Artemis hospital Artemis hospital, sector 51, Gurugram, Haryana, 122001 ECR/53/INST/HR/2013/RR-19	Dr Mukesh Patekar
8.	Sri Ram Cancer & super specialty Centre, Mahatma Gandhi Medical College & hospital, RIICO Industrial area, Jaipur, Rajasthan-302022	Institutional Ethics committee-Mahatma Gandhi Medical College & hospital, RIICO Industrial area, Jaipur, Rajasthan-302022 ECR/125/INST/RJ/2013/RR-19	Dr. Ajay Yadav
9.	All India institute of Medical Sciences, Veerbhadra Marg, Rishikesh, Uttarakhand, 249203	Ethics committee relating to Clinical trials-All India institute of Medical Sciences, Veerbhadra Marg, Rishikesh, Uttarakhand, 249203 ECR/736/Inst/UK/2015/RR-21	Dr. Amit Sherawat

10.	Indraprastha Apollo Hospitals, Sarita Vihar, Delhi -Mathura Road, New Delhi-110076.	Institutional Ethics Committee – Clinical Studies, Indraprastha Apollo Hospitals, Sarita Vihar, Delhi - Mathura Road, New Delhi-110076. ECR/5/Inst/DL/2013/RR-19	Dr Pratap Kishore Das
11.	MNJ Institute of Oncology & Regional Cancer Center-Red Hills, Lakadikapool, Hyderabad, Telangana-500004	MNJIORCC Ethics Committee, MNJ Institute of Oncology & Regional Cancer Center-Red Hills, Lakadikapool, Hyderabad, Telangana-500004 ECR/227/Inst/AP/2013/RR-19	Dr. Radhika Parimkayala
12.	J.K. Cancer Institute, Near Rawatpus Crossing Kanpur, Uttar Pradesh India-208002	Ethics Committee J K Cancer Kanpur, J.K. Cancer Institute, Near Rawatpus Crossing Kanpur, Uttar Pradesh India-208002 ECR/602/Inst/UP/2014/RR-21	Dr. Pramod Singh
13.	Spandana Oncology Centre 919, New No. 68, 28th Main Road, 9th Block, Jayanagar, Bangalore -560069	Spandana Oncology Centre 919, New No. 68, 28th Main Road, 9th Block, Jayanagar, Bangalore - 560069 ECR/1950/Inst/KA/2024	Dr. Satheesh CT
14.	ACE Hospital & Research Centre S. No. 32/2A, Gulwani Maharaj Road near abhishek, Pandurang colony, Erandwane, Pune, Maharashtra-411004	ACE Hospital Institutional Ethics committee, ACE Hospital & Research Centre S. No. 32/2A, Gulwani Maharaj Road near abhishek, Pandurang colony, Erandwane, Pune, Maharashtra-411004 ECR/474/Inst/MH/2013/RR-19	Dr. Tushar Patil

15.	Institute of Medical Sciences, Banaras Hindu University Department of Radiotherapy and Radiation Medicine: Institute of Medical Sciences, Banaras Hindu University. Varanasi-22 1005. Utar Pradesh .India	Institutional Ethics committee- Institute of medical sciences, Banaras Hindu University Department of Radiotherapy and Radiation Medicine: Institute of Medical Sciences, Banaras Hindu University. Varanasi-22 1005. Utar Pradesh India ECR/526/Inst/UP/2014/RR-20	Dr. Sunil Choudhary
-----	---	--	---------------------
